ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

311
Analysis
Health Care • China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
bearish•Sun Art Retail
•28 Feb 2025 09:20

Sun Art Retail (6808 HK): BABA Takes Massive Hit After Inking SPA @ HK$1.38

The SPA completed on the 27th Feb, triggering the MGO. Composite Doc to be dispatched on or before the 6th Mar. Under the terms of the SPA, an...

Logo
1.4k Views
Share
•25 Feb 2025 16:25

Pentamaster (1665 HK) Breaks Ahead Of Vote. Yet Pricing IS Fair

I was wrong on Henlius when the market started to turn. Here there's an absence of news; that's not a great situation. I'd trim, to exit my...

Logo
599 Views
Share
•25 Feb 2025 01:01

Pentamaster International (1665 HK): A Deal Break Will Be the Right Result for a Light Offer

The share price action suggests a deal break, which would be a fair result for a light offer. It is best to steer clear, as verifying whether a...

Logo
773 Views
Share
•20 Feb 2025 11:54

CNBM (3323 HK): Whitewash Waiver Secured. Next Is The Proration

I'm inclined to simply short outright here, if I had guaranteed take-no-action borrow. Especially as the price closes in on the tender price, and...

Logo
802 Views
Share
bullish•PEC Ltd.
•18 Feb 2025 10:18

PEC Ltd. (PEC SP): Privatisation Offer From Liberty Group

This is done. If small, illliquid arbs are your bent, and assuming late May payment, I'd pay up to S$0.79/share for a gross/annualised return of 6%...

Logo
745 Views
Share
x